Concepedia

Toshitaka Manda

TM

Statistics

Publications

36

Citations

1.7K

H-Index

21

Active since

1977

Affiliations

Mochida Pharmaceutical (Japan)(Current)

Fujisawa City Hospital

The University of Osaka

Astellas Pharma (Japan)

Toshitaka Manda is an author at Mochida Pharmaceutical (Japan) specializing in medicine, pharmacology, and tumor biology.

Top concepts

Publications per year

1977–2006

36

Publications

36

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

Hirotsugu Ueda, Toshitaka Manda, Sanae Matsumoto et al. · The Journal of Antibiotics · 1994 · 255 citations

New Antitumor Substances, FR901463, FR901464 and FR901465. II. Activities against Experimental Tumors in Mice and Mechanism of Action.

Hidenori Nakajima, Yasuhiro Hori, Hiroshi Terano et al. · The Journal of Antibiotics · 1996 · 211 citations · Full text

Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model

Ikuo Kawamura, Ryuichi Morishita, Naohiro Tomita et al. · Gene Therapy · 1999 · 117 citations

, , +7

Recombinant human tumor necrosis factor‐α: Thrombus formation is a cause of anti‐tumor activity

Kyoichi Shimomura, Toshitaka Manda, Sueo Mukumoto et al. · International Journal of Cancer · 1988 · 107 citations

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

Yuka Sasakawa, Yoshinori Naoe, Takeshi Inoue et al. · Biochemical Pharmacology · 2002 · 94 citations

, , +6

1–5 of 36